Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
ZYME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.97 - $17.70
Previous CloseN/A
Volume35.38K
Average Volume (3M)474.03K
Market Cap
$778.63M
Enterprise Value$678.46M
Total Cash (Recent Filing)$66.10M
Total Debt (Recent Filing)$18.51M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Apr 30, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding69,576,880
10 Day Avg. Volume743,842
30 Day Avg. Volume474,033
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.94
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.89
Enterprise Value/Ebitda-6.40
Forecast
1Y Price Target
$20.86Price Target Upside87.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityZymeworks' balance sheet resources should be sufficient to fund operations into the second half of 2027.
Regulatory MilestonesPotential regulatory decisions in the E.U. and China for zanidatamab are expected, which could be significant value inflection points.
Bears Say
Financial PerformanceZymeworks recorded a net loss of $0.31 per share, wider than the previously forecasted net loss of $0.12 per share, primarily due to lower-than-expected revenue.
---
Ownership Overview
22.79% Insiders
8.17% Mutual Funds
1.06% Other Institutional Investors
53.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $7.97 and its highest was $17.70 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $778.63M.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Apr 30, 2025 which is in 49 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Mar 05, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.099 by -$0.211.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -0.69.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 69,576,880 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.099. Following the earnings report the stock price went down -7.967%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
---
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.86 (87.93% Upside)
$20.86 (87.93% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 347.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $14.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.97%
12-Months-Change
Fundamentals
Return on Equity
-30.54%
Trailing 12-Months
Asset Growth
-20.28%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected significant achievements in regulatory approvals and strategic partnerships, indicating strong progress and an optimistic outlook for Zymeworks. Despite some financial setbacks such as increased net loss and a program discontinuation, the company maintains a solid financial position and continues to innovate across its pipeline.Read More>---
ZYME Stock 12 Month Forecast
Average Price Target
$20.86
▲(87.93% Upside)
Technical Analysis
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+36.01%
reiterated a buy rating 6 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +36.01% per trade.
---